
Kura Oncology, Inc. (NASDAQ:KURA – Free Report) – Equities research analysts at Brookline Capital Markets increased their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Tuesday, November 10th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of ($3.35) for the year, up from their previous estimate of ($3.48). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.21) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.97) EPS, FY2027 earnings at ($2.47) EPS and FY2028 earnings at ($2.30) EPS.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The business had revenue of $22.84 million during the quarter, compared to analysts’ expectations of $24.94 million.
Read Our Latest Research Report on KURA
Kura Oncology Stock Performance
Shares of NASDAQ:KURA traded up $0.34 during trading on Friday, hitting $7.77. 2,226,701 shares of the stock were exchanged, compared to its average volume of 2,345,466. The company has a market capitalization of $713.91 million, a price-to-earnings ratio of -2.35 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.71 and a current ratio of 3.60. Kura Oncology has a 1-year low of $6.75 and a 1-year high of $13.90. The company’s fifty day simple moving average is $10.17 and its 200-day simple moving average is $9.77.
Insiders Place Their Bets
In other news, insider Teresa Bair sold 8,442 shares of Kura Oncology stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.50, for a total value of $88,641.00. Following the completion of the transaction, the insider owned 187,002 shares of the company’s stock, valued at $1,963,521. This trade represents a 4.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian T. Powl sold 15,430 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $165,872.50. Following the completion of the sale, the insider owned 136,819 shares in the company, valued at $1,470,804.25. This represents a 10.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 153,881 shares of company stock worth $1,708,183 in the last 90 days. Company insiders own 7.60% of the company’s stock.
Institutional Investors Weigh In On Kura Oncology
A number of hedge funds and other institutional investors have recently modified their holdings of KURA. IFP Advisors Inc raised its position in shares of Kura Oncology by 136.5% in the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock valued at $28,000 after buying an additional 1,467 shares in the last quarter. Sterling Capital Management LLC boosted its stake in shares of Kura Oncology by 842.5% in the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock valued at $30,000 after buying an additional 2,519 shares during the period. Physician Wealth Advisors Inc. acquired a new stake in Kura Oncology during the third quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kura Oncology during the third quarter worth approximately $49,000. Finally, Allworth Financial LP acquired a new stake in Kura Oncology during the second quarter worth approximately $113,000.
Key Stories Impacting Kura Oncology
These are some of the KURA stories that stood out recently:
- Positive Sentiment: Kura reported third-quarter results, with KOMZIFTI revenue up 53%, and outlined plans to advance its pipeline in 2027. Product growth and pipeline progress could support investor sentiment. Article: Kura Oncology Reports Q3 Results; KOMZIFTI Revenue Grows 53%, Advances 2027 Pipeline Plans
- Neutral Sentiment: Kura said management will participate in two November investor conferences. The events may provide a forum for updates, but no new corporate or clinical news was disclosed in the announcement. Article: Kura Oncology to Participate in Two Investor Conferences in November
- Negative Sentiment: Brookline lowered its Q4 2026 EPS estimate, projecting a loss of $0.97 per share versus its prior $0.89 loss estimate—a cautionary counterpoint to the broader estimate increases. Analyst estimates
About Kura Oncology
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Featured Articles
- Five stocks we like better than Kura Oncology
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
